Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome01:13

The Proteasome

835
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
835
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

546
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
546
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

158
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
158
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

1.2K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
1.2K
The Proteasome Structure01:17

The Proteasome Structure

752
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
752

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorder.

American journal of human genetics·2026
Same author

KCTD3 deficiency disrupts axon initial segment organization and neurite outgrowth in a neurodevelopmental disorder mouse model.

Communications biology·2026
Same author

Expanding the clinical spectrum of RNU4ATAC-opathies: more frequent and diverse than assumed.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Pathological disruption of CELF2 shuttling causes neuronal hyperactivity, learning deficits, and seizures.

The Journal of clinical investigation·2026
Same author

Burst-Suppression EEG in Early Infantile Developmental and Epileptic Encephalopathies: Phenotype, Genotype, and Outcome.

Neurology·2026
Same author

Novel de novo dominant <i>PSMB10</i> variants in three patients with immune deficiency and liver disease.

Journal of human immunity·2026

Related Experiment Video

Updated: Jul 2, 2025

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein
10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein

Published on: November 10, 2012

16.7K

[Neurodevelopmental proteasomopathies: New disorders caused by proteasome dysfunction].

Silvestre Cuinat1, Stéphane Bézieau1, Wallid Deb1

  • 1Nantes Université, CHU Nantes, Service de génétique médicale, Nantes, France - Nantes Université, CNRS, Inserm, Institut du thorax, IRS-UN, Nantes, France.

Medecine Sciences : M/S
|February 27, 2024
PubMed
Summary

The ubiquitin-proteasome system (UPS) is vital for cellular processes. Recent findings link proteasome dysfunction to rare neurodevelopmental disorders, suggesting new diagnostic and therapeutic avenues.

More Related Videos

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay
07:05

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Published on: September 27, 2024

448
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

11.9K

Related Experiment Videos

Last Updated: Jul 2, 2025

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein
10:25

Monitoring of Ubiquitin-proteasome Activity in Living Cells Using a Degron dgn-destabilized Green Fluorescent Protein GFP-based Reporter Protein

Published on: November 10, 2012

16.7K
Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay
07:05

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Published on: September 27, 2024

448
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

11.9K

Area of Science:

  • Cellular Biology
  • Neuroscience
  • Genetics

Background:

  • The ubiquitin-proteasome system (UPS) is a fundamental eukaryotic pathway regulating protein homeostasis, cell cycle, and signaling.
  • Proteins are targeted for degradation via ubiquitination and subsequent processing by 26S proteasomes.
  • Emerging evidence connects pathogenic proteasome variants to rare neurodevelopmental disorders, termed neurodevelopmental proteasomopathies.

Approach:

  • This review synthesizes current research on proteasomal dysfunction in neurodevelopmental contexts.
  • It examines the molecular mechanisms underlying neurodevelopmental proteasomopathies.
  • The review assesses the potential of proteasomal pathways as targets for diagnostic biomarkers and therapeutic interventions.

Key Points:

  • Neurodevelopmental proteasomopathies are rare genetic syndromes.
  • Characterized by developmental delays, behavioral issues, distinct facial features, and multisystem anomalies.
  • Proteasome dysfunction is implicated in the pathogenesis of these disorders.

Conclusions:

  • Understanding proteasomal dysfunctions is crucial for diagnosing and treating neurodevelopmental proteasomopathies.
  • Identifying specific biomarkers related to proteasome function could revolutionize early detection.
  • Targeting the proteasome pathway offers a promising strategy for future therapeutic development.